Prevalence of the prothrombin gene variant 20210 G --> A among patients with myocardial infarction
Related Experiment Video
Updated: Oct 30, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
V R Arruda1, L H Siquiera, L C Chiaparini
1Hematology-Hemotherapy Center, State University of Campinas, SP Brazil. vrarruda@hotmail.com
Objective:
The aim of this study was to determine the prevalence of the prothrombin variant allele 20210A among survivors of myocardial infarction.
Background:
The prothrombin gene variant has been identified as a novel genetic risk factor for venous thrombosis. However, the risk of developing arterial thrombosis as a result of the presence of this mutated allele is unknown.
Methods:
The G-->A transition at position 20210 of the 3'-untranslated region was determined in 220 survivors of myocardial infarction and in 295 individuals from the general population.
Results:
The prevalence of heterozygotes for the prothrombin mutated allele was 3% among patients with myocardial infarction and 0.7% in the general population (P = 0.03). No age-related difference in the prevalence of the mutated allele was observed. However, for individuals over 45 years old the prevalence among females was higher than among males (5% vs. 0%).
Conclusion:
These data suggest that being heterozygote for the allele variant 20210A of the prothrombin gene could be a genetic risk factor for developing myocardial infarction.
Related Concept Videos
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Principles of Pharmacogenetics: Types of Genetic Variants
Acute Coronary Syndrome III: Diagnostic Studies
Pharmacogenetics of Drug Metabolism: Overview
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Coronary Artery Disease I: Introduction
